alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.1

CEO CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George F.
Colony, certify that:



| | 1. | I have reviewed this Amendment No. 1 on Form 10-K/A of Forrester Research, Inc.; and
| | -- | ------------------------------------------------------------------------------------



| | 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                      |  |  |  |                                                                                
|--------------------- |  |  |  | -------------------------------------------------------------------------------
|                      |  |  |  |                                                                                
|                      |  | 
|Dated: March 12, 2012 |  |  |  | /s/ George F. Colony                                                           
|                      |  |  |  | George F. Colony Chairman
of the Board of Directors and Chief Executive Officer
| (1)   | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|

| (2)   | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By:    | /s/Walter Davis                   |   |
|--------|--------|-----------------------------------|--------|
|   | Name:  | Walter Davis                      |   |
|   | Title: | President of                      |   |
|   |   | Demeter Management LLC,           |   |
|   |   | General Partner of the registrant |   |
|   | Date:  | May 14, 2010                      |   |
|   |   |                              |   |
Page 1 of 1

IN THE UNITED STATES DISTRICT COURT FOR THE

NORTHERN DISTRICT OF FLORIDA

PENSACOLA DIVISION

WILLIE J. GRIFFIN, JR.,

Petitioner,

vs. CASE NO.: 3:10cv342/RV/MD

BUTTERWORTH,

Respondent.

_____________________________________________________________________

O R D E R

This cause comes on for consideration upon the magistrate judge's report and

recommendation dated September 20, 2010. The petitioner has been furnished a

copy of the report and recommendation and has been afforded an opportunity to file

objections pursuant to Title 28, United St ates Code, Section 636(b)(1), and I have

made a de nov o determination of those portions to w hich an objection has been

made.

Having considered the report and recommendation and all objections thereto

timely filed, I have determined that the report and recommendation should be

adopted.

Accordingly, it is now ORDERED as follows:

1. The magistrat e j udge's report and recommendation is adopted and

incorporated by reference in this order.

2. The petition (doc. 1), construed as a § 2254 petition, is DISMISSED.

3. The petition (doc. 1), construed as a Rule 60(b) motion for relief from

judgment, is DENIED and this case is DISMISSED.

4. The clerk is directed to close the file.

5. A certificate of appealability is DENIED.

DONE AND ORDERED this 5th day of October, 2010.

/s/ Roger Vinson 

ROGER VINSON

SENIOR UNITED STATES DISTRICT JUDGE
[Federal Register Volume 72, Number 40 (Thursday, March 1, 2007)]
[Notices]
[Page 9339]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-914]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Office of the National Coordinator for Health Information 
Technology; American Health Information Community Meeting

ACTION: Change in meeting location to California.

-----------------------------------------------------------------------

SUMMARY: This notice announces the 12th meeting of the American Health 
Information Community in accordance with the Federal Advisory Committee 
Act (Pub. L. No. 92-463, 5 U.S.C., App.). The American Health 
Information Community will advise the Secretary and recommend specific 
actions to achieve a common interoperability framework for health 
information technology (IT).

DATES: March 13, 2007, from 8 a.m. to 1:30 p.m. (Pacific time).

New Address: Computer History Museum, 1401 N. Shoreline Boulevard, 
Mountain View, California 94043.

For Further Information: Visit http://www.hhs.gov/healthit/ahic.html.

SUPPLEMENTARY INFORMATION: The meeting will include presentations by 
the Quality Workgroup; Population Health/Clinical Care Connections 
Workgroup; Consumer Empowerment Workgroup; and Confidentiality, Privacy 
and Security Workgroup. It will also feature a panel presentation on 
Privacy and Security issues.
    The general public is invited to participate in person at the 
Computer History Museum in Mountain View, CA. Alternatively, the public 
may participate remotely via the Web. The Community meeting will be 
available on the NIH Web site at: http://www.videocast.nih.gov/.
    If you have special needs for the meeting, please contact (202) 
690-7151.

    Dated: February 21, 2007.
Judith Sparrow,
Director, American Health Information Community, Office of Programs and 
Coordination, Office of the National Coordinator for Health Information 
Technology.
[FR Doc. 07-914 Filed 2-28-07; 8:45 am]
BILLING CODE 4150-24-M
# C_2010213EN.01001801.xml

| 6.8.2010 | EN | Official Journal of the European Union | C 213/18 |
| --- | --- | --- | --- |

6.8.2010

EN

Official Journal of the European Union

C 213/18

---

Non-opposition to a notified concentration

(Case COMP/M.5896 — Credit Suisse/Barclays/Ionbond Group)

(Text with EEA relevance)

2010/C 213/09

On 30 July 2010, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5896. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5896. EUR-Lex is the on-line access to the European law.

---
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5267 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 5267

   To amend the Controlled Substances Act to clarify the process for 
    denying, revoking, or suspending a registration to manufacture, 
distribute, or dispense a controlled substance, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 13, 2018

 Mr. Welch (for himself and Ms. Judy Chu of California) introduced the 
   following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on the Judiciary, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL

 
   To amend the Controlled Substances Act to clarify the process for 
    denying, revoking, or suspending a registration to manufacture, 
distribute, or dispense a controlled substance, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ELIMINATION OF FORMAL PROCESS BY WHICH A REGISTRANT WHO IS 
              SUBJECT TO AN ORDER TO SHOW CAUSE MAY SUBMIT A CORRECTIVE 
              ACTION PLAN.

    Section 304(c) of the Controlled Substances Act (21 U.S.C. 824(c)) 
is amended--
            (1) in paragraph (2)--
                    (A) in subparagraph (A), by inserting ``and'' at 
                the end;
                    (B) in subparagraph (B), by striking ``; and'' and 
                inserting a period; and
                    (C) by striking subparagraph (C) (relating to 
                submission of a corrective action plan);
            (2) by striking paragraph (3) (relating to clarification of 
        a corrective action plan); and
            (3) by redesignating paragraphs (4) and (5) as paragraphs 
        (3) and (4), respectively.

SEC. 2. DEFINITION OF IMMINENT DANGER TO THE PUBLIC HEALTH OR SAFETY 
              FOR PURPOSES OF SUSPENDING A REGISTRATION.

    Section 304(d)(2) of the Controlled Substances Act (21 U.S.C. 
824(d)(2)) is amended by striking ``there is a substantial likelihood 
of'' and inserting ``there is probable cause to believe that''.
                                 <all>
```
EXHIBIT 32.02








CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002














In connection with the Quarterly Report of Managed Futures Profile HV, L.P. (the “Partnership”) on Form 10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christian Angstadt, Chief Financial Officer of Demeter Management LLC, the general partner of the Partnership, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:




(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.




























By:
/s/  Christian AngstadtName:
Christian AngstadtTitle:
Chief Financial Officer ofDemeter Management LLC,General Partner of the registrantDate:
May 14, 2010
# C_2011077EN.01000601.xml

| 11.3.2011 | EN | Official Journal of the European Union | C 77/6 |
| --- | --- | --- | --- |

11.3.2011

EN

Official Journal of the European Union

C 77/6

---

Euro exchange rates (1)

1

10 March 2011

2011/C 77/06

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3817 |
| JPY | Japanese yen | 114,78 |
| DKK | Danish krone | 7,4581 |
| GBP | Pound sterling | 0,85655 |
| SEK | Swedish krona | 8,8115 |
| CHF | Swiss franc | 1,2914 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 7,7820 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 24,362 |
| HUF | Hungarian forint | 272,98 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7065 |
| PLN | Polish zloty | 3,9915 |
| RON | Romanian leu | 4,1920 |
| TRY | Turkish lira | 2,1823 |
| AUD | Australian dollar | 1,3782 |
| CAD | Canadian dollar | 1,3416 |
| HKD | Hong Kong dollar | 10,7640 |
| NZD | New Zealand dollar | 1,8795 |
| SGD | Singapore dollar | 1,7566 |
| KRW | South Korean won | 1 551,67 |
| ZAR | South African rand | 9,5160 |
| CNY | Chinese yuan renminbi | 9,0845 |
| HRK | Croatian kuna | 7,3925 |
| IDR | Indonesian rupiah | 12 134,82 |
| MYR | Malaysian ringgit | 4,1962 |
| PHP | Philippine peso | 60,066 |
| RUB | Russian rouble | 39,4100 |
| THB | Thai baht | 41,976 |
| BRL | Brazilian real | 2,2919 |
| MXN | Mexican peso | 16,4954 |
| INR | Indian rupee | 62,4290 |

Currency

Exchange rate

USD

US dollar

1,3817

JPY

Japanese yen

114,78

DKK

Danish krone

7,4581

GBP

Pound sterling

0,85655

SEK

Swedish krona

8,8115

CHF

Swiss franc

1,2914

ISK

Iceland króna

NOK

Norwegian krone

7,7820

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

24,362

HUF

Hungarian forint

272,98

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7065

PLN

Polish zloty

3,9915

RON

Romanian leu

4,1920

TRY

Turkish lira

2,1823

AUD

Australian dollar

1,3782

CAD

Canadian dollar

1,3416

HKD

Hong Kong dollar

10,7640

NZD

New Zealand dollar

1,8795

SGD

Singapore dollar

1,7566

KRW

South Korean won

1 551,67

ZAR

South African rand

9,5160

CNY

Chinese yuan renminbi

9,0845

HRK

Croatian kuna

7,3925

IDR

Indonesian rupiah

12 134,82

MYR

Malaysian ringgit

4,1962

PHP

Philippine peso

60,066

RUB

Russian rouble

39,4100

THB

Thai baht

41,976

BRL

Brazilian real

2,2919

MXN

Mexican peso

16,4954

INR

Indian rupee

62,4290

---

(1)  Source: reference exchange rate published by the ECB.

1

Source

---
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano 

Richard H. Bernstein, Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 April 1, 2015

d0325

Order 

Clerk

April 1, 2015

150055

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 150055

COA: 315031

Wayne CC: 12-009043-FC

XAVIER ERIC SMITH,

Defendant-Appellant. 

_________________________________________/

On order of the Court, the application for leave to appeal the July 29, 2014 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court.
[Federal Register Volume 72, Number 41 (Friday, March 2, 2007)]
[Notices]
[Page 9542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-968]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate 
proposals for support through the RAID program by making available to 
the research community, on a competitive basis, NCI new agent 
development contract resources for the preclinical development of drugs 
and biologics. The outcome of the evaluation will be a decision whether 
NCI should support the request and make available contract resources 
for support through the RAID program to the research community and NCI 
new agent development for the preclinical development of drugs and 
biologics. The research proposals and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the proposed research projects, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Rapid Access to Intervention Development.
    Date: March 20-21, 2007.
    Time: 1 p.m.-5 p.m.
    Agenda: To evaluate the Rapid Access to Intervention Development 
Portfolio.
    Place: National Institutes of Health, Executive Plaza North, 
Conference Room J, 6130 Executive Boulevard, Rockville, MD 20852.
    Contact Person: Phyllis G. Bryant, Executive Secretary, Program 
Analyst, Developmental Therapeutics Program, National Cancer 
Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 
20892. (301) 496-8720.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: February 22, 2007
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-968 Filed 3-1-07; 8:45 am]
BILLING CODE 4140-01-M
Page 1 of 2

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF FLORIDA

GAINESVILLE DIVISION

VICTOR MANUEL CELORIO,

Plaintiff,

v. CASE NO. 1:11cv79-SPM/GRJ

GOOGLE INC., ON DEMAND 

BOOKS, LLC, JASON EPSTEIN, 

AND JOHN DOES 1-3.

Defendants.

____________________________/

ORDER

THIS CAUSE comes before the Court upon the Magistrate Judge’s report

and recommendation (doc. 38) dated April 30, 2012. Plaintiff was furnished a

copy, and has filed objections (doc. 39). 

Pursuant to Title 28, United States Code, Section 636(b)(1), I find that the

report and recommendation should be adopted. Accordingly it is

ORDERED AND ADJUDGED:

1. The report and recommendation (doc. 38) is adopted and

incorporated by reference in this order.

2. Defendants On Demand Books and Jason Epstein’s Motion to

Dismiss for Lack of Jurisdiction (doc. 22) is granted.

Case 1:11-cv-00079-RV-GRJ Document 41 Filed 05/17/12 Page 1 of 2
Page 2 of 2

3. Plaintiff’s request for jurisdictional discovery is denied.

DONE AND ORDERED this 16th day of May, 2012.

s/ Stephan P. Mickle 

Stephan P. Mickle

Senior United States District Judge

CASE NO. 1:11cv79-SPM/GRJ

Case 1:11-cv-00079-RV-GRJ Document 41 Filed 05/17/12 Page 2 of 2
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 1 of 6
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 2 of 6
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 3 of 6
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 4 of 6
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 5 of 6
Case 3:11-cv-00075-RS-EMT Document 1 Filed 02/16/11 Page 6 of 6
2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
 3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the company as of, and for, the periods presented in this report;
 4.
    
    The companys other certifying officer(s) and I are responsible for establishing and
maintaining disclosing controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the company and have:
 a.
    
    Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the company, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;b.
    
    Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted
accounting principles;c.
    
    Evaluated the effectiveness of the companys disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluations; andd.
    
    Disclosed in this report any change in the companys internal control over financial
reporting that occurred during the period covered by the annual report that has materially
affected, or is reasonable likely to materially affect, the companys internal control over
financial reporting; and
 5.
    
    The companys other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the companys auditors and the
audit committee of the companys board of directors (or persons performing the equivalent
functions):
 a.
    
    All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the companys ability to record, process, summarize and report financial information; andb.
    
    Any fraud, whether or not material, that involves management or other employees who
have a significant role in the companys internal control over financial reporting.
  By:
    
    /s/ Frank AbbottFrank AbbottInterim Chief Financial OfficerInterim Financial Director